Eli Lilly sweeps the rest of the BACE work out of the pipeline following their latest major setback on Alzheimer’s
Eli Lilly has suffered through the biggest setbacks in late-stage drug development work for Alzheimer’s — piling up high-profile failures for semagacestat, solanezumab and just months ago lanabecestat after it became apparent that the BACE approach was a non-starter in symptomatic patients. Today, it’s signaling that the company is now ready to fold their hand early if it doesn’t look like they have a reasonable chance to go on to win the pot.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.